Sefi Rosenfeld
Director - Pre-clinical & Early Clinical Development Nasus Pharma
Dr. Yosef (Sefi) Rosenfeld is Director of Pre-Clinical and Early Clinical Development at Nasus Pharma, where he leads the company’s intranasal drug delivery pipeline, spanning dry-powder and liquid formulations across multiple therapeutic areas, toward first-in-human studies. He holds a Ph.D. in Biological Chemistry from the Weizmann Institute of Science and has spent over 15 years advancing novel drug delivery platforms, with senior R&D and regulatory roles at PolyPid, NeuroDerm, and SilkIt. His work bridges preclinical pharmacology, pharmacokinetics, and GLP safety studies with regulatory strategy, having authored nonclinical sections for IND, NDA, and MAA submissions. He has published 13 peer-reviewed articles and holds two patents in drug delivery and immune modulation.
Seminars
- Explore the unique challenges associated with evaluating powder-based intranasal products in preclinical studies, including administration techniques, dose accuracy, and reproducibility across animal models
- Understand the strengths and limitations of commonly used preclinical approaches for assessing safety, pharmacokinetics, deposition, and product performance when developing nasal powders
- Review practical strategies developers are using to generate more relevant preclinical data and improve confidence when progressing powder-based products toward clinical development
